FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a method for the treatment of psoriatic arthritis in humans, including the stage of administering to a person at least one dose of a neutralizing antibody that binds to human IL-17A and human IL-17F.
EFFECT: invention provides for treatment of arthritis with improved indicators of clinical effects.
17 cl, 16 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
| PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
